NNBP.OB - a swing trading approach

[sebfr]

Hi,

my strategy :
but today at open, at about 0.054
target at 0.070
stop loss at 0.045

Technically, NNBP is oversold...We can try to play for a rebound...We have a divergence in MACD and RSI. Macd close nears 0. And we have an Bullish Engulfing with a high volume...Price is very far of his MA50...

[gmarc66]

NNBP moving on no news, but seems to have broken the last high .105 (g-spot) and is also experiencing highest vol. ever...could be a double gpattern forming?

looks interesting. lets see if it keeps going in the short term.

glta

[gmarc66]

Sorry, Sorry..there is news today that came in at around 12:30pm today...my stupid micrccrap didnt show it!  PPS is approaching a new hod as i type, hod at this point is .115, very nice block buys coming in slow and steady.


Nanobac Pharmaceuticals Films Stunning Details of Nanoparticles Using New Technology


2006-08-22 12:26 ET - News Release
TAMPA, Fla. -- (Business Wire) -- Aug. 22, 2006
Company Website: http://www.nanobaclabs.com

     Nanobac Pharmaceuticals, Inc. (OTCBB:NNBP) ("Nanobac" or
"the Company") today announced that its scientists have obtained new
details about interactions of drugs with calcifying nanoparticles
(CNPs), known also as nanobacteria, using award-winning light
microscope technology.
     The images show nanoparticles being affected by a therapeutic drug
ingredient, and offer proof of concept that new microscope technology
can detect real-time processes surrounding calcifying nanoparticles,
which contain harmful calcifying constituents found in diseases such
as kidney stones and atherosclerosis.
     "This marks a watershed in the Company's ability to witness
interactions between drug ingredients and calcifying nanoparticles,"
commented Nanobac Co-Chairman Dr. Benedict Maniscalco. "These images
also demonstrate clear differences between CNPs and inorganic apatite,
offering further proof that CNPs are distinct from inorganic apatite
particles."
     The video and still images were obtained by Nanobac scientists
Dr. Neva Ciftcioglu and Grace Mathew at Nanobac laboratories in the
NASA Johnson Space Center in Houston. The images will be released
once the processes they recorded have been validated.
     The success is an early result of a collaboration agreement
between Nanobac and the Fetzer Memorial Trust to photograph the
replication cycle of disease-related calcifying particles (also known
as nanobacteria or Calcifying Nanoparticles), using light microscopes
to break the 200 nanometer ("nm") resolution barrier. The breakthrough
may allow Nanobac scientists to determine if calcification, which
occurs in most diseases on the leading causes of death list, has a
biological mechanism, which would make it susceptible to therapy.
     Until now, scientists had to 'fix' or inactivate such
nanoparticles to see below the 200 nm threshold using electron
microscopy, which precluded observing real-time processes.
     The "CytoViva"(TM) microscope system, developed at Auburn
University and marketed by Aetos Technologies, can resolve details at
or below 100 nm and detect particles as small as 50 nm, representing a
significant improvement over conventional light microscopes. The
CytoViva(TM) system was selected in June by R&D Magazine as one of the
top 100 most technologically significant products introduced to the
marketplace in 2006. The award is often referred to as the 'Oscar of
Inventions.'

     About Nanobac Pharmaceuticals

     Nanobac Pharmaceuticals, Inc. is a life sciences company dedicated
to the discovery and development of products and services to improve
people's health through the detection and treatment of Calcifying
Nanoparticles (CNPs), otherwise known as "nanobacteria". The Company's
pioneering research is establishing the pathogenic role of CNPs in
soft tissue calcification, particularly in coronary artery, prostate,
and vascular disease.
     Nanobac's drug discovery and development is focused on new and
existing compounds that effectively inhibit, destroy or neutralize
CNPs. Nanobac manufactures In Vitro Diagnostic (IVD) kits and reagents
for detecting Calcifying Nanoparticles. IVD products include a line of
assays, proprietary antibodies and reagents for uniquely recognizing
CNPs. Nanobac's BioAnalytical Services works with biopharmaceutical
partners to develop and apply methods for avoiding, detecting, and
inactivating or eliminating CNPs from raw materials.
     Nanobac Pharmaceuticals, Inc. is headquartered in Tampa, Florida.
For more information, visit our website at: http://www.nanobac.com .

[gmarc66]

I'm really upset at myself for not buying this when i saw the gspot breakout...this was a beautiful gpattern.

Sorry, for not keeping  it updated...i think i got so frustrated with myself for not buying..i tried to ignore its continuing uptrend..it was laughing at me

Hope someone got some of the action.

glta

julia

[la-onda]

quotation from fous TTT.net; applaud 

NNBP.OB is a very speculative small cap biotech with some interesting developments and a "significant announcement" next week.

Take a minute and read this PR from today:

Nanobac Pharmaceuticals Releases New Portrait of Calcifying Nanoparticles, Related Announcement to Follow
Thursday October 26, 9:50 am ET

TAMPA, Fla.--(BUSINESS WIRE)--Scientists for Nanobac Pharmaceuticals Inc. (OTCBB:NNBP - News; "Nanobac" or "the Company") have published a new outlook on the role of calcifying nanoparticles (CNPs) in diseases such as atherosclerosis and kidney stones, setting the groundwork for what company officials call a "significant" announcement next week.

Entitled "What are Calcifying Nanoparticles?" the document on the company's Web site provides, for the first time, investors and journalists with a clear picture of the state of science on CNPs, formerly known as nanobacteria, and summarizes the role CNPs play in one of the most pervasive medical conditions in existence: calcification of arteries and organs.

"We decided to publish this summary so journalists and investors could have a clear idea of what the particles are before we release research next week that will show surprising new results," explained Nanobac Co-Chair Dr. Benedict Maniscalco.

The summary was completed following a conference earlier this month at the University of Auburn, sponsored by the Fetzer Memorial Trust, a non-profit foundation dedicated to bringing leading edge technologies to the forefront.

"After a lot of probing questions from some of the leading scientists in their field, our organization was able to assemble a document that accurately describes the state of knowledge on what CNPs are, what they do to us, and why interest in this pathogen is growing," Dr. Maniscalco added.

For years scientists have been struggling to assemble a snapshot of the "state of knowledge" about CNPs. The document was assembled to fill that gap.

One of the issues raised about CNPs is whether they are any different from calcified crystals that are found in kidney stones and hardening of the arteries.

"Our announcement (including video evidence) next week will show there is a difference, and that difference will explain a lot about why present therapies against calcification have been ineffective," Maniscalco said.

"In preparation for that announcement, and because there have been debates over what the particles actually are, we decided to gather the state of knowledge to date for everybody to see and discuss," he concluded.

Final work is still being done on video microscopy evidence assembled by Nanobac scientists, in preparation for its release next week. The new summary document "What Are Calcifying Nanoparticles (CNPs)?" is available at http://www.nanobac.com/content/what-are-cnps.htm.


It appears that they have some exiting news to be announcing next week and i wouldn't mind finding out what that news is and enjoying the ride if this rallies. And we all know how biotechs act on "significant news". Depending on how price reacts prior to the news will effect the volatility of the announcement. If we see a lot of buying into next week it might be wise to sell the news. So we'll have to see how price reacts.

On sep 12th wall street resources inc released a very in depth report on NNBP with a mean 12 month price target of .91, which is partially what initiated its last run. Its fairly long and dry reading, but has a lot of significant info about the company and its marketplace.
http://www.wallstreetresources.net/pdf/fc/NNBP.pdf

thursday NNBP made a bullish breakout of its descending channel on increased volume and bouncing off the 50ma putting NNBP back in the spot light for traders.

I'll be looking for entry tomorrow, hopefully near the top of the descending channel near .215 or so.

-fous

[la-onda]

chart update, ready to rumble 

[la-onda]

rumble part 1 
have a nice weekend
Oliver

[la-onda]

rumble part 2

[la-onda]

  bad day for NNBP, suggested stop by fous (@.30) was not holding.

I am still invested, let´s see what will happen tomorrow

[la-onda]

out @ .275 $ with >15% profit 

[la-onda]

sold too early 

[la-onda]

fyi:
First Live Video of Calcifying Nanoparticles Provides Possible Key to Chronic Disease Condition
Thursday November 2, 12:47 pm ET
New Study Reveals Distinction Between Calcifying Nanoparticles and Inorganic Crystals

TAMPA, Fla.--(BUSINESS WIRE)--Scientists today released the first live video footage of calcifying nanoparticles, or CNPs, that might play a basic role in calcifying diseases ranging from heart disease to prostate disease and kidney stones. Calcification is a harmful condition found in most diseases on the leading-cause-of-death list, including cardiovascular disease -- the nation's single leading cause of death. Even the lesser problem of kidney stones results in more than one million doctor visits and 250,000 hospitalizations every year.
"We used a new, high-definition Nikon microscope system, validated with a new award-winning system from Aetos Technologies, which allowed real-time tracking of calcifying nanoparticles (CNPs) at a size of around 100 nanometers," explained Dr. Neva Ciftcioglu, Science Director of Nanobac Pharmaceuticals, which produced the video. "Before these technologies were created recently, we had to chemically treat the nanoparticles to see below the 200 nanometer threshold, which kept us from observing live processes."

This video, for the first time, illustrates: 1) A decalcifying agent dissolving calcified structures while the particles inside seem unaffected and are released to potentially begin the calcification process again. 2) By contrast, inorganic crystals exposed to the same agent are dissolved without releasing nanoparticles.

"Although preliminary, this is a significant scientific and medical finding," observed Dr. Arnold Mandell, professor emeritus at UCSD School of Medicine, research professor at the Emory University School of Medicine and a MacArthur Prize Fellow in the medical sciences. "It brings new scientific support to earlier findings that the pathophysiology of calcification in vascular and other organ systems might involve calcifying nanoparticles. More generally, it suggests that an as yet to be fully explored universe of nanoparticles might play critical roles in medical disorders. It also supports previous evidence that these particles can be viewed as distinct from inorganic crystals and form the basis for an exciting and independent area of research." Dr. Mandell was present as an independent observer when the results were announced by Nanobac scientists.

"While these are early findings, we believe they merit serious investigation," explained Nanobac Co-Chairman Dr. Benedict Maniscalco. "Further investigation of these particles will be necessary to determine if this is the first step toward proving a biological mechanism for calcifying diseases, and will hopefully lead to drug therapies to treat calcification. These results, which were obtained from animal sourced particles, will now be applied to particles obtained from human blood."

Evidence of CNPs was first reported in the 1990s, by Nanobac scientists and other scientists in peer-reviewed journals. The new video was first unveiled at a recent invitation-only Auburn University conference of leading microscopy and biomedical scientists, organized by the Fetzer Memorial Trust. The Trust specializes in supporting leading-edge medical technologies, and has been collaborating with Nanobac on this project since early 2006.

[joet]

sold the news  La-onda, you did fine!!

[Michael]

sold too early 

Well timing is all about the time period you look at 

As Joet said you got it right!

I didn't go to the first NNBP party but I promised myself that if I could ever get a cheap ticket to a Nanobac Party I would show up. It seems pretty cheap today so I trying to pick up a few tickets 

This is a spectacular speculative stock but I am confident that this will not be the last time NNBP is on a roll.

As always when evaluating a Biotech stock there are three parameters to take into consideration:

• The competition
• The potential market
• The likelihood that they will succeed in developing a commercially viable drug

The competition is minimal as this is a paradigm shift; the potential market is north of 500 billion USD so the speculation is around the likelihood of them developing a commercially viable drug.

I think they have a good chance but look at it like this even if the chance is 1% that can still justify a much, much, much higher market cap when the potential market is more than 500 billion USD.

We will see but I think the risk/reward ratio is favorable today.

[joet]

Howdie Michael,
Do you have a time frame for this penny pick??  Sounds like you are not concerned with the technical breakdown...  it seems like it could see sub .10 again easily??  Will you stop out at .15?  Target?

Is PCYG still one of your collections?  I still have it and wish i had bought more at 2.50...  will hold it until hopefully the big money finds it.

Cheers Joe